Spots Global Cancer Trial Database for A Study of Famitinib in Patients With Advanced Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Famitinib in Patients With Advanced Colorectal Cancer
Official Title: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer
Study ID: NCT01762293
Study Description
Brief Summary: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable. The purpose of this study is to determine whether Famitinib can improve progression free survival compared with placebo in patients with advanced colorectal cancer who failed in previous at least two lines of chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer center, Sun Yet-sen University, Guangzhou, Guangdong, China
Beijing Cancer Hospital, Peking University, Beijing, , China
Contact Details
Name: Shen Lin, M.D
Affiliation: Beijing Cancer Hospital, Peking University
Role: PRINCIPAL_INVESTIGATOR
Name: Ruihua Xu, M.D
Affiliation: Cancer Center, Sun Yet-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
